-
Je něco špatně v tomto záznamu ?
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
Y. Miyazaki, H. Tuechler, G. Sanz, J. Schanz, G. Garcia-Manero, F. Solé, JM. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, MM. Le Beau, ML. Slovak, V. Santini, M. Lübbert,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie, práce podpořená grantem
- MeSH
- Asijci * MeSH
- běloši * MeSH
- lidé MeSH
- míra přežití MeSH
- myelodysplastické syndromy * diagnóza etiologie genetika mortalita MeSH
- přežití bez známek nemoci MeSH
- retrospektivní studie MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.
Cleveland Clinic Cleveland OH United States
Department of Pathology University of New Mexico Albuquerque NM United States
Elisabethinen Hospital Linz Austria
Federal University of Ceara Fortaleza Brazil
Hanusch Hospital and Ludwig Boltzmann Cluster Oncology Vienna Austria
Heinrich Heine University Hospital Dusseldorf Germany
Hopital Avicenne Assistance Publique Hopitaux de Paris University of Paris XIII Bobigny France
Hopital Cochin AP HP University of Paris 5 Paris France
Hospital Universitario La Fe Valencia Spain
Hospital Universitario Vall d'Hebron Barcelona Spain
Institut de Recerca contra la Leucèmia Josep Carreras Barcelona Spain
Institute of Hematology and Blood Transfusion Praha Czech Republic
James P Wilmot Cancer Center University of Rochester Medical Center Rochester NY United States
L Boltzmann Institute for Leukemia Research Vienna Austria
MDS Unit Ematologia AOU Careggi Università degli Studi di Firenze Firenze Italy
Medical University of Vienna Vienna Austria
Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
St James's University Hospital Leeds United Kingdom
Stanford Cancer Institute Stanford CA United States
The University of Texas MD Anderson Cancer Center Houston TX United States
University Hospital of Innsbruck Innsbruck Austria
University Medical Center Clinics of Haematology and Medical Oncology Göttingen Germany
University of Chicago Comprehensive Cancer Research Center Chicago IL United States
University of Dundee Dundee United Kingdom
University of Freiburg Medical Center Faculty of Medicine Freiburg Germany
VU University Medical Center Cancer Center Amsterdam Amsterdam The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19028208
- 003
- CZ-PrNML
- 005
- 20190819115011.0
- 007
- ta
- 008
- 190813s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.leukres.2018.08.022 $2 doi
- 035 __
- $a (PubMed)30219650
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Miyazaki, Yasushi $u Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Electronic address: y-miyaza@nagasaki-u.ac.jp.
- 245 10
- $a Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS / $c Y. Miyazaki, H. Tuechler, G. Sanz, J. Schanz, G. Garcia-Manero, F. Solé, JM. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, MM. Le Beau, ML. Slovak, V. Santini, M. Lübbert, J. Maciejewski, S. Machherndl-Spandl, SMM. Magalhaes, M. Pfeilstöcker, MA. Sekeres, WR. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespi, AA. van de Loosdrecht, U. Germing, D. Haase, PL. Greenberg,
- 520 9_
- $a Clinical features of myelodysplastic syndromes (MDS) could be influenced by many factors, such as disease intrinsic factors (e.g., morphologic, cytogenetic, molecular), extrinsic factors (e.g, management, environment), and ethnicity. Several previous studies have suggested such differences between Asian and European/USA countries. In this study, to elucidate potential differences in primary untreated MDS between Japanese (JPN) and Caucasians (CAUC), we analyzed the data from a large international database collected by the International Working Group for Prognosis of MDS (300 and 5838 patients, respectively). JPN MDS were significantly younger with more severe cytopenias, and cytogenetic differences: less del(5q) and more +1/+1q, -1/del(1p), der(1;7), -9/del(9q), del(16q), and del(20q). Although differences in time to acute myeloid leukemia transformation did not occur, a significantly better survival in JPN was demonstrated, even after the adjustment for age and FAB subtypes, especially in lower, but not in higher prognostic risk categories. Certain clinical factors (cytopenias, blast percentage, cytogenetic risk) had different impact on survival and time to transformation to leukemia between the two groups. Although possible confounding events (e.g., environment, diet, and access to care) could not be excluded, our results indicated the existence of clinically relevant ethnic differences regarding survival in MDS between JPN and CAUC patients. The good performance of the IPSS-R in both CAUC and JP patients underlines that its common risk model is adequate for CAUC and JP.
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a Asijci $7 D044466
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 12
- $a běloši $7 D044465
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a myelodysplastické syndromy $x diagnóza $x etiologie $x genetika $x mortalita $7 D009190
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Tuechler, Heinz $u L. Boltzmann Institute for Leukemia Research, Vienna, Austria.
- 700 1_
- $a Sanz, Guillermo $u Hospital Universitario La Fe, Valencia, Spain.
- 700 1_
- $a Schanz, Julie $u University Medical Center, Clinics of Haematology and Medical Oncology, Göttingen, Germany.
- 700 1_
- $a Garcia-Manero, Guillermo $u The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- 700 1_
- $a Solé, Francesc $u Institut de Recerca contra la Leucèmia Josep Carreras, Barcelona, Spain.
- 700 1_
- $a Bennett, John M $u James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, United States.
- 700 1_
- $a Bowen, David $u St James's University Hospital, Leeds, United Kingdom.
- 700 1_
- $a Fenaux, Pierre $u Hopital Avicenne, Assistance Publique-Hopitaux de Paris (AP-HP)/University of Paris XIII, Bobigny, France.
- 700 1_
- $a Dreyfus, Francois $u Hopital Cochin, AP-HP, University of Paris V, Paris, France.
- 700 1_
- $a Kantarjian, Hagop $u The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
- 700 1_
- $a Kuendgen, Andrea $u Heinrich-Heine University Hospital, Dusseldorf, Germany.
- 700 1_
- $a Malcovati, Luca $u Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo and University of Pavia, Pavia, Italy.
- 700 1_
- $a Cazzola, Mario $u Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo and University of Pavia, Pavia, Italy.
- 700 1_
- $a Cermak, Jaroslav $u Institute of Hematology and Blood Transfusion, Praha, Czech Republic.
- 700 1_
- $a Fonatsch, Christa $u Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Le Beau, Michelle M $u University of Chicago Comprehensive Cancer Research Center, Chicago, IL, United States.
- 700 1_
- $a Slovak, Marilyn L $u Department of Pathology, University of New Mexico, Albuquerque, NM, United States.
- 700 1_
- $a Santini, Valeria $u MDS Unit, Ematologia, AOU Careggi, Università degli Studi di Firenze, Firenze, Italy.
- 700 1_
- $a Lübbert, Michael $u University of Freiburg Medical Center, Faculty of Medicine, Freiburg, Germany.
- 700 1_
- $a Maciejewski, Jaroslaw $u Cleveland Clinic, Cleveland, OH, United States.
- 700 1_
- $a Machherndl-Spandl, Sigrid $u Elisabethinen Hospital, Linz, Austria.
- 700 1_
- $a Magalhaes, Silvia M M $u Federal University of Ceara, Fortaleza, Brazil.
- 700 1_
- $a Pfeilstöcker, Michael $u Hanusch Hospital and Ludwig Boltzmann Cluster Oncology, Vienna, Austria.
- 700 1_
- $a Sekeres, Mikkael A $u Cleveland Clinic, Cleveland, OH, United States.
- 700 1_
- $a Sperr, Wolfgang R $u Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
- 700 1_
- $a Stauder, Reinhard $u University Hospital of Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Tauro, Sudhir $u University of Dundee, Dundee, United Kingdom.
- 700 1_
- $a Valent, Peter $u Department of Internal Medicine I, Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria.
- 700 1_
- $a Vallespi, Teresa $u Hospital Universitario Vall d'Hebron, Barcelona, Spain.
- 700 1_
- $a van de Loosdrecht, Arjan A $u VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Germing, Ulrich $u Heinrich-Heine University Hospital, Dusseldorf, Germany.
- 700 1_
- $a Haase, Detlef $u University Medical Center, Clinics of Haematology and Medical Oncology, Göttingen, Germany.
- 700 1_
- $a Greenberg, Peter L $u Stanford Cancer Institute, Stanford, CA, United States.
- 773 0_
- $w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 73, č. - (2018), s. 51-57
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30219650 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190819115245 $b ABA008
- 999 __
- $a ok $b bmc $g 1433357 $s 1066668
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 73 $c - $d 51-57 $e 20180906 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
- LZP __
- $a Pubmed-20190813
